PL2490684T3 - Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu - Google Patents

Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu

Info

Publication number
PL2490684T3
PL2490684T3 PL10825771T PL10825771T PL2490684T3 PL 2490684 T3 PL2490684 T3 PL 2490684T3 PL 10825771 T PL10825771 T PL 10825771T PL 10825771 T PL10825771 T PL 10825771T PL 2490684 T3 PL2490684 T3 PL 2490684T3
Authority
PL
Poland
Prior art keywords
efficacy
methods
reduce
increase
side effects
Prior art date
Application number
PL10825771T
Other languages
English (en)
Inventor
Valter D. Longo
Changhan Lee
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Publication of PL2490684T3 publication Critical patent/PL2490684T3/pl

Links

Classifications

    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00Administration; Management
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65Sausages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Business, Economics & Management (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Theoretical Computer Science (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Economics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10825771T 2009-10-22 2010-10-22 Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu PL2490684T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
EP10825771.8A EP2490684B1 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (1)

Publication Number Publication Date
PL2490684T3 true PL2490684T3 (pl) 2018-07-31

Family

ID=43900993

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10825771T PL2490684T3 (pl) 2009-10-22 2010-10-22 Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu

Country Status (13)

Country Link
US (2) US20110118528A1 (pl)
EP (1) EP2490684B1 (pl)
JP (1) JP2013508411A (pl)
CN (1) CN102753162A (pl)
AU (2) AU2010310515B2 (pl)
BR (1) BR112012009423A2 (pl)
CA (1) CA2779282C (pl)
DK (1) DK2490684T3 (pl)
ES (1) ES2659353T3 (pl)
PL (1) PL2490684T3 (pl)
PT (1) PT2490684T (pl)
RU (1) RU2549954C2 (pl)
WO (1) WO2011050302A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822178T3 (es) * 2012-10-22 2021-04-29 Univ Southern California Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels
AU2014284399B2 (en) 2013-07-01 2017-10-26 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944088C (en) * 2014-03-28 2022-06-21 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
RU2687750C2 (ru) * 2014-04-02 2019-05-16 Юниверсити Оф Саутерн Калифорния Лечение аутоиммунной реакции и рассеянного склероза
CA3108664A1 (en) 2015-04-16 2016-10-20 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
BR112017023748A2 (pt) 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
US20200010562A1 (en) * 2015-09-21 2020-01-09 Ifom Fondazione Istituto Firc Di Oncogia Molecolare New therapeutic strategies against blood cancer
JP2019504073A (ja) * 2016-01-12 2019-02-14 ユニバーシティ オブ サザン カリフォルニア 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
RU2018131403A (ru) 2016-02-15 2020-03-17 Юниверсити Оф Саутерн Калифорния Комбинации лекарственных средств и способы стимуляции эмбрионоподобной регенерации для лечения сахарного диабета и других заболеваний
EP4218751A3 (en) 2016-02-23 2024-03-06 Cancer Research Technology Ltd Dietary product devoid of at least two non essential amino acid
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
AU2019236242A1 (en) 2018-03-15 2020-10-01 University Of Southern California Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology
DE212018000421U1 (de) * 2018-07-18 2021-03-01 Andreas Michalsen Auswirkungen einer kurzzeitigen Diät, die Fasten imitiert, auf die Lebensqualität und die Verträglichkeit einer Chemotherapie bei Patientinnen mit Krebs
CA3119100C (en) 2018-11-09 2024-06-04 Valter D. Longo Nutrition bar for intermittent fasting-mimicking
JP2022530671A (ja) 2019-04-30 2022-06-30 ユニバーシティ オブ サザン カリフォルニア アルツハイマー病(ad)の介入のための断食模倣食(fmd)
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
CN114173578A (zh) * 2019-05-14 2022-03-11 迪美公司 用于治疗癌症的组合物和方法
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP7376718B2 (ja) * 2019-12-13 2023-11-08 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
EP4161501A4 (en) 2020-06-03 2024-07-03 Faeth Therapeutics, Inc. Formulations for personalized methods of treatment
US12109184B2 (en) 2020-06-04 2024-10-08 Faeth Therapeutics, Inc. Personalized methods of treating cancer
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
US20240000125A1 (en) * 2020-12-17 2024-01-04 Fondazione Irccs Istituto Nazionale Dei Tumori Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823B1 (en) 2021-03-30 2025-04-30 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Reduced caloric intake and anticancer agents for the treatment of cancer
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学(Cn) 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
EP4599826A1 (en) 2024-02-06 2025-08-13 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Leucine for use in the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
DK1017379T3 (en) * 1997-03-17 2015-02-16 Btg Int Ltd Therapeutic compositions comprising ketone compounds and precursors thereof
WO2001006983A2 (en) * 1999-07-22 2001-02-01 Incell Corporation, Llc Fatty acids to minimize cancer therapy side effects
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
AU2005296271A1 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
ES2891733T3 (es) * 2007-03-28 2022-01-31 Univ Southern California Inducción de la resistencia diferencial al estrés y usos de la misma
CA2706656A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Also Published As

Publication number Publication date
AU2010310515A1 (en) 2012-05-17
AU2010310515B2 (en) 2016-01-07
RU2549954C2 (ru) 2015-05-10
EP2490684B1 (en) 2018-01-03
EP2490684A4 (en) 2016-05-04
CA2779282C (en) 2017-12-05
WO2011050302A3 (en) 2011-08-25
RU2012118588A (ru) 2013-11-27
CN102753162A (zh) 2012-10-24
EP2490684A2 (en) 2012-08-29
US20110118528A1 (en) 2011-05-19
US20210209516A1 (en) 2021-07-08
BR112012009423A2 (pt) 2017-06-13
CA2779282A1 (en) 2011-04-28
ES2659353T3 (es) 2018-03-14
AU2016201607A1 (en) 2016-03-31
AU2016201607B2 (en) 2017-11-30
JP2013508411A (ja) 2013-03-07
WO2011050302A2 (en) 2011-04-28
PT2490684T (pt) 2018-04-02
DK2490684T3 (en) 2018-04-09

Similar Documents

Publication Publication Date Title
PT2490684T (pt) Métodos e formulações nutricionais para aumentar a eficácia e reduzir os efeitos secundários do tratamento oncológico
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
ZA201302979B (en) Dianosis and treatment relating to th2 inhibition
EP2645957A4 (en) ELIMINATION OF FAT BY NON-INVASIVE HYPERTHERMIC TREATMENT
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
SG10201509279QA (en) Compositions and methods for the prevention and treatment of cancer
IL218575A0 (en) Treatment of cancer
PL2510072T3 (pl) Terapeutyczne i kosmetyczne kompozycje elektroluminescencyjne
ZA201300692B (en) Administration of hypoxia activated prodrugs and antiagiogenic agents for the treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2651894A4 (en) THIOSEMICARBAZONE COMPOUNDS FOR CANCER TREATMENT
IL214757A0 (en) Compositions and methods to prevent and/or treat cancer with pa-card
IL233080B (en) Bisarylsulfonamides used to treat inflammation and cancer
PL2375912T3 (pl) Kompozycje i sposoby leczenia uczucia dyskomfortu gardła
ZA201408057B (en) Compositions and methods for the treatment of moderate to severe pain
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
GB0916686D0 (en) Treatment of cancer
ZA201005770B (en) The treatment of damaged skin
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201020304D0 (en) Treatment and prevention of pain
AU2010900897A0 (en) Skin cancer prevention and treatment
AU2010904813A0 (en) Skin cancer prevention and treatment